Brief: 3Sbio Says China's NMPA Accepted Its Ind Application For Bevacizumab Biosimilar In Mainland China
14/09/2020 15:19
Sept 14 (Reuters) - 3SBio Inc 1530.HK :
* CHINA'S NMPA ACCEPTED ITS IND APPLICATION FOR BEVACIZUMAB
BIOSIMILAR IN MAINLAND CHINA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS8mlS3Q
Further company coverage: 1530.HK
((Reuters.Briefs@thomsonreuters.com;))